Modified release dosage forms of skeletal muscle relaxants
View Patent ↗A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.
1. A pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise:
an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and
an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof;
wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg;
wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (C max ) of 19.851±5.8765 ng/mL of cyclobenzaprine HCl and an AUC 0-168 of 736.60±259.414 ng·hr/mL.
2. A pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise:
an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and
an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof;
wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg;
wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (C max ) of 19.851±5.8765 ng/mL of cyclobenzaprine HCl and an AUC 0-∞ of 779.889±277.6349 ng·hr/mL.
3. A pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise:
an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and
an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof;
wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 15 mg;
wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (C max ) of 8.315±2.1635 ng/mL of cyclobenzaprine HCl and an AUC 0-168 of 318.30±114.657 ng·hr/mL.
4. A pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise:
an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and
an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof;
wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 15 mg;
wherein following a single oral administration of the pharmaceutical dosage form, the pharmaceutical dosage form provides a maximum blood plasma concentration (C max ) of 8.315±2.1635 ng/mL of cyclobenzaprine HCl and an AUC 0-∞ of 354.075±119.8037 ng·hr/mL.
5. A pharmaceutical dosage form comprising a population of extended release beads, wherein said extended release beads comprise:
an active-containing core particle comprising cyclobenzaprine hydrochloride as the active; and
an extended release coating comprising a water insoluble polymer membrane surrounding said core, wherein said water insoluble polymer membrane comprises a polymer selected from the group consisting of ethers of cellulose, esters of cellulose, cellulose acetate, ethyl cellulose, polyvinyl acetate, neutral copolymers based on ethyl acrylate and methyl methacrylate, copolymers of acrylic and methacrylic acid esters with quaternary ammonium groups, pH-insensitive ammonio methacrylic acid copolymers, and mixtures thereof;
wherein the total amount of cyclobenzaprine hydrochloride in the pharmaceutical dosage form is 30 mg;
wherein following a single oral administration, said pharmaceutical dosage form provides a maximum blood plasma concentration (C max ) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine and an AUC 0-168 within the range of about 80% to 125% of about 740 ng·hr/mL.
6. The pharmaceutical dosage form of any one of claims 1 - 4 , wherein said pharmaceutical dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddled @ 50 rpm) in 900 mL of 0.1N HCl at 37° C. exhibits a release profile substantially corresponding to the following pattern:
after 2 hours, no more than 40% of the total amount of the cyclobenzaprine hydrochloride is released;
after 4 hours, from about 40-65% of the total amount of the cyclobenzaprine hydrochloride is released; and
after 8 hours, from about 60-85% of the total amount of the cyclobenzaprine hydrochloride is released.
7. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said pharmaceutical dosage form when dissolution tested using United States Pharmacopoeia Apparatus 2 (paddled @ 50 rpm) in 900 mL of 0.1N HCl at 37° C. exhibits a release profile substantially corresponding to the following pattern:
after 2 hours, no more than 40% of the total amount of the cyclobenzaprine hydrochloride is released;
after 4 hours, from about 40-65% of the total amount of the cyclobenzaprine hydrochloride is released;
after 8 hours, from about 60-85% of the total amount of the cyclobenzaprine hydrochloride is released; and
after 12 hours, from about 75-85% of the total amount of the cyclobenzaprine hydrochloride is released.
8. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said extended release coating comprises from about 7% to 12% by weight of the extended release beads.
9. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said extended release coating further comprises a water soluble polymer selected from the group consisting of methylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, polyethylene glycol, polyvinylpyrrolidone and mixtures thereof.
10. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said extended release coating further comprises a plasticizer selected from the group consisting of triacetin, tributyl citrate, triethyl citrate, acetyl tri-n-butyl citrate, diethyl phthalate, dibutyl sebacate, polyethylene glycol, polypropylene glycol, castor oil, acetylated mono- and di-glycerides, and mixtures thereof.
11. The pharmaceutical dosage form of claim 10 , wherein said extended release coating comprises about 10% to 25% by weight of said plasticizer.
12. The pharmaceutical dosage form of any one of claims 1 - 5 , in the form of a capsule.
13. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said extended release coating comprises about 1% to about 15% by weight of the extended release beads.
14. The pharmaceutical dosage form of any one of claims 1 - 5 , wherein said pharmaceutical dosage form further comprises a seal coating layer comprising hydroxypropyl methylcellulose or hydroxypropylcellulose.